Source: Annual Congress 2012 - Anti-infective treatment and resistance in respiratory infections
Disease area: Respiratory critical care, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
S. Herrera, E. Fernández, A. Cervera, M. C. Aguar, F. Sanz, J. Blanquer, E. Chiner (Valencia, Alicante, Spain; Valencia, Sri Lanka). Macrolides vs quinolones in Legionella pneumonia treatment: CAPAVANT group. Valencia (Spain). Eur Respir J 2012; 40: Suppl. 56, 4367

Member's Comments

No comment yet.

Related content which might interest you: The impact of antimicrobial resistance on the cost-effectiveness of empirical treatment of community-acquired pneumonia (CAP) in France (FR), Belgium (BE) and Germany (DE) Source: Annual Congress 2007 - Community-acquired pneumonia: from aetiology to complication Year: 2007 Hospitalisation costs for community-acquired pneumonia (CAP) in France (F), Germany (D), Japan (J) and USA Source: Eur Respir J 2004; 24: Suppl. 48, 8s Year: 2004 Antibacterial activity of telithromycin and comparators against pathogens isolated from patients with community-acquired pneumonia (CAP) in PROTEKT years 1–5 (1999–2004) Source: Eur Respir J 2006; 28: Suppl. 50, 350s Year: 2006 Fluoroquinolone versus β-lactam plus macrolide in patients hospitalized with community-acquired pneumonia (CAP) Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia Year: 2008 Antibacterial activity of telithromycin (TEL) and comparators against pathogens isolated from patients with community-acquired pneumonia (CAP) in the PROTEKT study 1999–2002 Source: Eur Respir J 2004; 24: Suppl. 48, 186s Year: 2004 Resistance of problematic gram(-) respiratory pathogens selected from in-patients (Yaroslavl, Russia, 2011) Source: Annual Congress 2012 - Management of severe respiratory infections Year: 2012 Legionella pneumonia in patients hospitalized with community-acquired pneumonia (CAP) in Norway Source: Annual Congress 2012 - Management of severe respiratory infections Year: 2012 High proportion of fluoroquinolone mono-resistant mycobacterium tuberculosis (MTB) strains in Pakistan (2010-2012) Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 Gender and other risk factors for multidrug-resistant (MDR) tuberculosis (TB) among migrants to Milan, Italy Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis Year: 2011 Community-acquired pneumonia trough enterobacteriaceae and p. aeruginosa: diagnosis, incidence, and predictors. The German CAPNETZ Source: Annual Congress 2009 - Respiratory infection caused by Pseudomonas aeruginosa Year: 2009 Use of pneumonia severity index in Spain to decide hospitalization among patients with community-acquired pneumonia (CAP). (Nacar Study) Source: Eur Respir J 2005; 26: Suppl. 49, 637s Year: 2005 Optimizing treatment for community-acquired pneumonia in Denmark (The optiCAP study) Source: International Congress 2018 – Pneumonia: from the community to the intensive care unit Year: 2018 The efficiency of moxifloxacin (MOX) in community-acquired pneumonias (CAP) treatment while the initial antibacterial therapy (IAT) was inefficient Source: Eur Respir J 2005; 26: Suppl. 49, 638s Year: 2005 Mycobacterium tuberculosis (TB) drug resistance in the sanitary area of Aviles, Asturias (Spain) Source: Annual Congress 2008 - Epidemiology and clinical management of multidrug-resistant and extensively drug-resistant tuberculosis Year: 2008 Surveillance of multi-drug resistance and phenotypes of Acinetobacter baumannii isolates producing extended-spectrum-beta-lactamases (ESBLs) from hospital acquired pneumonia patients in west China Source: Annual Congress 2009 - Aetiology and diagnosis of lower respiratory tract infections Year: 2009 Relevance of correct antibiotic choice in community-acquired pneumonia (CAP) Source: Annual Congress 2005 - Community-acquired pneumonia: clinical approaches Year: 2005 Change in the susceptibility pattern of Streptococcus pneumoniae (SP) and risk factors (RF) for antibiotic resistance (AR) in patients with community-acquired pneumonia (CAP) Source: Eur Respir J 2003; 22: Suppl. 45, 546s Year: 2003 Lower overall healthcare costs with telithromycin (TEL) versus clarithromycin (CLA) in community-acquired pneumonia (CAP) Source: Eur Respir J 2003; 22: Suppl. 45, 152s Year: 2003 Pneumococcal pneumonia: an old disease with radically-new approaches for antibiotic therapy Source: Annual Congress 2005 - Outcome in severe pneumonia Year: 2005 Community-acquired paediatric pneumonia (CAPP). Is antibiotic treatment universally required? Source: Eur Respir J 2001; 18: Suppl. 33, 171s Year: 2001